These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32767959)

  • 21. Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors.
    Jin RY; Tang T; Zhou S; Long X; Guo H; Zhou J; Yan H; Li Z; Zuo ZY; Xie HL; Tang YP
    Bioorg Chem; 2020 May; 98():103737. PubMed ID: 32193031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
    Zhang K; Lai F; Lin S; Ji M; Zhang J; Zhang Y; Jin J; Fu R; Wu D; Tian H; Xue N; Sheng L; Zou X; Li Y; Chen X; Xu H
    J Med Chem; 2019 Aug; 62(15):6992-7014. PubMed ID: 31117517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
    Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
    Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
    Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
    Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.
    Giddens AC; Gamage SA; Kendall JD; Lee WJ; Baguley BC; Buchanan CM; Jamieson SMF; Dickson JMJ; Shepherd PR; Denny WA; Rewcastle GW
    Bioorg Med Chem; 2019 Apr; 27(8):1529-1545. PubMed ID: 30850264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors.
    Rodrigues DA; Guerra FS; Sagrillo FS; de Sena M Pinheiro P; Alves MA; Thota S; Chaves LS; Sant'Anna CMR; Fernandes PD; Fraga CAM
    ChemMedChem; 2020 Mar; 15(6):539-551. PubMed ID: 32022441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity.
    Tian C; Yang C; Wu T; Lu M; Chen Y; Yang Y; Liu X; Ling Y; Deng M; Jia Y; Zhou Y
    Bioorg Med Chem Lett; 2021 Sep; 48():128271. PubMed ID: 34284105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
    Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
    Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
    Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
    Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening.
    Gu D; Cheng G; Zhang M; Zhou YB; Li J; Sheng R
    Bioorg Med Chem; 2021 Jan; 29():115863. PubMed ID: 33199203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors.
    Wu P; Su Y; Liu X; Yang B; He Q; Hu Y
    Bioorg Med Chem; 2012 May; 20(9):2837-44. PubMed ID: 22480851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
    Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
    Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives.
    Yin Y; Wu X; Han HW; Sha S; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
    Org Biomol Chem; 2014 Dec; 12(45):9157-65. PubMed ID: 25296388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New halogenated chalcones with cytotoxic and carbonic anhydrase inhibitory properties: 6-(3-Halogenated phenyl-2-propen-1-oyl)-2(3H)-benzoxazolones.
    Bilginer S; Gul HI; Erdal FS; Sakagami H; Gulcin I
    Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900384. PubMed ID: 32285546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.